Our look is new. Our purpose is the same. Learn more about our brand evolution.
Ever since joining the FSH Society’s Board of Directors, Abilene-resident Wendy Shack has been hoping to gather the region’s FSHD patients and families for a meeting. Last Saturday, she saw the […]
The San Diego-based biotech company, aTyr Pharma, Inc., released findings on March 30, 2016, from a Phase 1b/2 clinical trial of its experimental therapy Resolaris in adult facioscapulohumeral muscular dystrophy (FSHD) patients. While […]
Our first-ever basketball tournament, at Boston’s legendary TD Garden–home of the Boston Celtics–was a rousing success. Teams from Acceleron Pharma, SHIFT Communications, O’Connor Drew, Mouse Specifics, Social Sports Boston and […]
FSH Society President & CEO Daniel Perez has submitted his annual testimony to the U.S. House Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies (LHHSE). […]
The Muscular Dystrophy Coordinating Committee (MDCC), a congressionally authorized group of representatives from federal agencies and patient advocates, recently released an updated version of its Action Plan for the Muscular […]
